Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine

A. Pardanani, A. V. Hoffbrand, J. H. Butterfield, A. Tefferi

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


We used three to six courses of 2-chlorodeoxyadenosine (2-CdA) (2-h infusion at 0.14mg/kg per day × 5 days) given over a period of 3-36 months to treat four patients with aggressive systemic mast cell disease (SMCD) that was resistant to interferon-alpha (IFN-α). Treatment with 2-CdA resulted in a major response in two patients and a good partial response in one other patient (75% overall response). Treatment was well tolerated and duration of remission in responding patients ranges from 2 months to 4+ years since the completion of treatment with 2-CdA.

Original languageEnglish (US)
Pages (from-to)127-131
Number of pages5
JournalLeukemia Research
Issue number2
StatePublished - Feb 2004


  • 2-Chlorodeoxyadenosine
  • Interferon-alpha
  • Systemic mast cell disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine'. Together they form a unique fingerprint.

Cite this